THERMO FISHER SCIENTIFIC INC.TMO
THERMO FISHER SCIENTIFIC INC. Financial Overview 2021–2025
Updated Jul 10, 2026Thermo Fisher Scientific successfully replaced a staggering $7.26 billion pandemic revenue cliff by executing one of the most aggressive acquisition rollups in the life sciences sector. The core investment thesis is clear: the company engineered a massive operational pivot, completely offsetting the collapse of its COVID-19 testing business by buying its way into higher-margin clinical research and bioproduction markets.
This inorganic growth strategy reshaped the top line, as total revenue grew from $39.21 billion in FY2021 to $44.56 billion in FY2025. Management deployed immense capital to execute this shift, highlighted by the $15.99 billion purchase of PPD, the $3.21 billion takeover of Olink, and a $4.1 billion carve-out of Solventum's filtration unit. Despite absorbing these integrations and navigating macroeconomic softness in academic end-markets, severe cost discipline pushed the adjusted operating income margin to 22.7% by the end of FY2025. The underlying operations remain a powerful cash engine, generating $6.34 billion in free cash flow in FY2025 to fund aggressive capital returns, including $3.0 billion in share repurchases in Q1 2026 alone.
The market has rewarded this margin resilience and steady capital deployment. At the close of FY2025, the stock traded at $579.45, reflecting institutional confidence in an optimized portfolio that now relies entirely on structural biopharma demand rather than transient health crises.
Recent Developments (Q4 2025 and Q1 2026)
Thermo Fisher accelerated its portfolio transformation in Q1 2026 by acquiring clinical trial data provider Clario Holdings for $9.099 billion, partially funded by issuing $3.76 billion in senior notes. Management concurrently announced the divestiture of its microbiology unit for $1.075 billion. Operations remained strong, with Q1 2026 revenue rising 6% year-over-year to $11.0 billion and operating income growing 9% to $1.9 billion. Free cash flow doubled to $825 million.
A leadership restructuring took effect in March 2026, elevating Gianluca Pettiti to President and Chief Operating Officer. Bull case: The Clario integration provides immediate scale in clinical data solutions, complementing robust biopharma demand. Bear case: Ongoing declines across academic and government end-markets threaten to drag down overall momentum. The stock traded at 28.4x earnings as of May 1, 2026, commanding a premium valuation despite legacy segment softness.
What to watch: microbiology unit divestiture progress; academic end-market demand
Rev
$42.88B
FY2024
NI
$6.34B
FY2024
EPS
$16.58
FY2024
OCF
$8.67B
FY2024
Year-over-year comparison from 10-K annual reports
Data from SEC Company Facts
Recent SEC Filings
THERMO FISHER SCIENTIFIC INC. 8-K Report, Shareholder Vote Results (May 26, 2026)
Thermo Fisher Scientific Inc. (TMO) filed an 8-K on May 26, 2026, detailing the outcomes of its Annual Meeting of Shareholders held on May 20, 2026. The primary focus of the filing is the voting results on key corporate matters. Notably, all incumbent nominees for the Board of Directors were overwhelmingly re-elected for one-year terms, indicating strong shareholder confidence in the current leadership and governance structure. However, a significant development from the meeting is the shareholder rejection of the non-binding, advisory proposal on the compensation of the Company's named executive officers. This outcome suggests a divergence of opinion between shareholders and the board regarding executive pay practices. Despite this advisory vote, the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, was ratified by a substantial majority of shareholders, ensuring continued auditor oversight.
THERMO FISHER SCIENTIFIC INC. 8-K Report, Financial Results (Apr 23, 2026)
Thermo Fisher Scientific Inc. (TMO) has filed an 8-K report on April 23, 2026, to announce its financial results for the fiscal quarter ended March 28, 2026. The press release detailing these results is furnished as an exhibit to this filing. Investors should refer to the attached Exhibit 99.1 for the complete financial performance and operational details of the company during this period. While this 8-K primarily serves to furnish the earnings release, it's crucial for investors to review the information provided in Exhibit 99.1 to understand TMO's recent performance, any forward-looking statements made, and management's commentary on key business drivers and financial condition. The filing itself does not contain extensive new information beyond referencing the earnings announcement.
THERMO FISHER SCIENTIFIC INC. 8-K Report, Corporate Update (Mar 24, 2026)
Thermo Fisher Scientific Inc. (TMO) announced the successful completion of its acquisition of Clario Holdings, Inc. on March 24, 2026. This strategic move is expected to bolster Thermo Fisher's capabilities and market position within its industry. While the filing itself is brief and primarily serves to announce the closing of this transaction, investors should anticipate future updates regarding the integration of Clario's operations and its impact on Thermo Fisher's financial performance and strategic direction. The acquisition of Clario Holdings, Inc. represents a significant development for Thermo Fisher. Investors will be keen to understand the financial terms of the deal, the expected synergies, and how Clario's business will be integrated into Thermo Fisher's existing portfolio. This 8-K filing serves as a formal notification of the transaction's closure, and further details concerning the financial implications and operational integration are likely to be disclosed in subsequent filings or investor communications.
THERMO FISHER SCIENTIFIC INC. 8-K Report, Material Agreement (Feb 12, 2026)
Thermo Fisher Scientific Inc. (TMO) has announced the successful completion of a significant public offering of senior notes, raising approximately $3.76 billion in net proceeds. This capital infusion comprises four tranches of notes with varying interest rates and maturity dates, ranging from 2031 to 2046. The primary stated purpose of this offering is to fund a portion of the cash consideration for the previously announced acquisition of Clario Holdings, Inc., underscoring the company's strategic growth initiatives. While the acquisition of Clario is subject to customary closing conditions and regulatory approvals, TMO has outlined plans for the proceeds. Pending the acquisition's completion, a portion of the funds may be allocated to general corporate purposes, including potential future acquisitions, debt repayment, working capital, capital expenditures, or share repurchases. The notes are unsecured general obligations of the company and rank equally with existing unsecured and unsubordinated debt. The filing also details provisions related to early redemption, change of control scenarios, and standard covenants limiting certain secured debt and major asset dispositions.
THERMO FISHER SCIENTIFIC INC. 8-K Report, Financial Results (Jan 29, 2026)
Thermo Fisher Scientific Inc. (TMO) has filed an 8-K report on January 28, 2026, announcing its financial results for the fiscal quarter and year ended December 31, 2025. The press release containing these detailed results is furnished as an exhibit to this filing, providing investors with the latest performance data. This filing serves as the primary vehicle for investors to access TMO's fourth-quarter and full-year 2025 financial performance. While specific figures are not detailed within the 8-K itself, investors are directed to the furnished press release (Exhibit 99.1) for comprehensive insights into revenue, earnings, and other key financial metrics. This information is crucial for assessing the company's recent operational success and its trajectory heading into the next fiscal year.
View all 8-K filings →